Accelerate Diagnostics Partners with BioCheck to Distribute CLIA Analyzer and SARS-CoV-2 Antibody Tests

Accelerate Diagnostics, Inc. (Tucson, AZ, USA) and BioCheck, Inc. (San Francisco, CA, USA) have entered into a commercial supply and collaboration agreement for the distribution of the BioCheck MS-FAST, a fully-automated chemiluminescence immunoassay analyzer, along with BioCheck's SARS-CoV-2 tests for the detection of IgG and IgM antibodies. Accelerate will distribute the analyzer and tests in North America, Europe and the Middle East.

The BioCheck MS-FAST system and SARS-CoV-2 chemiluminescence-based tests are capable of processing blood, serum, or plasma samples in 30 minutes to detect antibodies that confirm exposure and potential immunity to COVID-19. BioCheck is commercializing the MS-FAST analyzer (automated chemiluminescent immunoassay system) and associated COVID-19 and other cytokine, metabolic, and cardiovascular test kits to allow convenient, instant, and accurate diagnosis of disease markers with a bench top instrument. The company has applied for the US Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for its SARS-Cov-2 tests.


“Serological testing for the detection of antibodies to COVID-19 plays a critical role in identifying patients who have likely developed some degree of immunity to the virus,” said Romney Humphries, Accelerate Diagnostics' Chief Scientific Officer. “The BioCheck SARS-CoV-2 tests will help determine which medical professionals can more safely serve on the front lines treating COVID-19 patients, as well as when it may be safe for recovered patients to resume normal activities.”

“We are eager to play our part in the fight against this devastating virus,” said Jack Phillips, Accelerate Diagnostics' Chief Executive Officer. “BioCheck, Inc., in conjunction with its strategic partner Sophonix Co., Ltd., has been clinically validating its fully automated serologic tests in Wuhan, China since the early stages of the pandemic, and we are delighted to partner with them to bring this critical technology to as many patients and healthcare workers as possible.”

“We are excited to announce this partnership with Accelerate Diagnostics, which will bring our MS-FAST instrument and SARS-CoV-2 IgG and IgM tests to patients across multiple geographies and help prevent the further spread of COVID-19 around the world,” said Dr. Amy Zhang, Vice President and General Manager of BioCheck. “Working with Sophonix, we have spent seven years developing the MS-FAST system to be more sensitive and easily deployable than many current products on the market.”

Related Links:
Accelerate Diagnostics, Inc.
BioCheck, Inc.